Company intelligence / Profile preview

Hainan Helpson Medical & Biotechnology

Haikou, Hainan, China

Ownership: Private
Development stage: Other

Overview

Candesartan tablets approved by National Medical Products Administration as generic, passed consistency evaluation. Dry Eye Disease Therapeutic Device to launch in Q1 2025 in China, with production, commercialization, and third-party testing completed. Portfolio includes more than 20 branded and generic drugs as well as nutritional supplements and innovative medical devices.

Therapeutic areas: NephrologyCardiovascularImmunologyOphthalmologyGastroenterologyInfectious DiseasesNeurologyMetabolic DisordersDermatologyPsychiatry
Modalities: Small moleculeBiologicMedical device
Industry: Biotech

Drug pipeline

1 asset

vitamin b6 for injection

Unknown

Beyond the preview

Go deeper on Hainan Helpson Medical & Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hainan Helpson Medical & Biotechnology.

Explore the full profile